MedTrace Logo

Immunogenetic Modulators of Mucosal Protection From HIV-1

NCT03701802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 812

Last updated 2020-11-03

No results posted yet for this study

Summary

This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1 acquisition. The study will collect mucosal and peripheral blood samples for a detailed analysis of longitudinal immune responses, while also obtaining samples for genetic characterization to understand how variants in CD101 and UBE2V1 may modulate host mucosal responses and HIV-1 infection risk.

Conditions

  • HIV Infections
  • HSV-2 Infection

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Kenya Medical Research Institute

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • Jairam Lingappa, MD, PhD · University of Washington

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701802 on ClinicalTrials.gov